{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:08:18Z","timestamp":1788869298168,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cllc.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:09:43Z","timestamp":1781208583000},"page":"24-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non\u2013Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial"],"prefix":"10.1016","volume":"27","author":[{"given":"Ying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dairong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhong","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruilian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buhai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2026.06.003_bib0001","unstructured":"World Health Organization (WHO). Lung cancer, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer."},{"key":"10.1016\/j.cllc.2026.06.003_bib0006","article-title":"Advances and future perspectives of HER2 mutations in non-small lung cancer (NSCLC), especially in China","volume":"32:10732748251347572","author":"Liu","year":"2025","journal-title":"Cancer Control"},{"issue":"6","key":"10.1016\/j.cllc.2026.06.003_bib0007","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/1759-7714.13419","article-title":"Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer","volume":"11","author":"Wei","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2026.06.003_bib0008","unstructured":"cBioPortal for cancer genomics. https:\/\/www.cbioportal.org\/study\/summary?id=nsclc_ctdx_msk_2022."},{"issue":"11","key":"10.1016\/j.cllc.2026.06.003_bib0009","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1111\/1759-7714.13681","article-title":"Prognostic factors for survival in patients with metastatic lung adenocarcinoma: an analysis of the SEER database","volume":"11","author":"Campos-Balea","year":"2020","journal-title":"Thorac Cancer"},{"issue":"24","key":"10.1016\/j.cllc.2026.06.003_bib0010","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1002\/cncr.32461","article-title":"Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers","volume":"125","author":"Offin","year":"2019","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.cllc.2026.06.003_bib0011","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody\u2013drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.cllc.2026.06.003_bib0012","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.cllc.2026.06.003_bib0013","unstructured":"AstraZeneca. Press release. Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2026\/enhertu-approved-in-two-her2-early-bc-settings.html, 2026."},{"issue":"31","key":"10.1016\/j.cllc.2026.06.003_bib0016","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non\u2013small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2026.06.003_bib0017","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.06.003_bib0018","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT248","article-title":"Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the phase 2 DESTINY-Lung05 (DL-05) trial","volume":"84","author":"Cheng","year":"2024","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.cllc.2026.06.003_bib0020","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jtho.2025.07.129","article-title":"Final analysis results and patient-reported outcomes from DESTINY-Lung02\u2014A dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC","volume":"20","author":"J\u00e4nne","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2026.06.003_bib0021","doi-asserted-by":"crossref","first-page":"176","DOI":"10.21147\/j.issn.1000-9604.2022.03.03","article-title":"National guidelines for diagnosis and treatment of lung cancer 2022 in China (English version)","volume":"34","year":"2022","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"10.1016\/j.cllc.2026.06.003_bib0024","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jtho.2022.09.217","article-title":"Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): a phase 3, open-label, randomized controlled trial","volume":"18","author":"Zhou","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2026.06.003_bib0025","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","article-title":"Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial","volume":"14","author":"Wu","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"23","key":"10.1016\/j.cllc.2026.06.003_bib0026","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non\u2013small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cllc.2026.06.003_bib0027","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1470-2045(25)00012-9","article-title":"Trastuzumab rezetecan, a HER2-directed antibody\u2013drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study","volume":"26","author":"Li","year":"2025","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2026.06.003_bib0028","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.cllc.2026.06.003_bib0029","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2159-8290.CD-24-0306","article-title":"Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers","volume":"15","author":"Wilding","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2026.06.003_bib0030","doi-asserted-by":"crossref","first-page":"517","DOI":"10.18632\/oncotarget.28444","article-title":"Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)","volume":"14","author":"Assi","year":"2023","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.cllc.2026.06.003_bib0031","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cllc.2011.06.008","article-title":"Retrospective analysis of third-line and fourth-line chemotherapy for advanced non\u2013small-cell lung cancer","volume":"13","author":"Asahina","year":"2012","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"10.1016\/j.cllc.2026.06.003_bib0032","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2004.08.158","article-title":"Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non\u2013small-cell lung cancer","volume":"22","author":"Miller","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2026.06.003_bib0033","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1378\/chest.126.2.347","article-title":"Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung","volume":"126","author":"Nordquist","year":"2004","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.cllc.2026.06.003_bib0034","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12916-024-03844-8","article-title":"Non-small cell lung cancer in ever-smokers vs never-smokers","volume":"23","author":"Burt","year":"2025","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.cllc.2026.06.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.43107","article-title":"Trastuzumab deruxtecan for ERBB2-mutant metastatic non-small cell lung cancer with or without brain metastases: a secondary analysis of randomized clinical trials","volume":"8","author":"J\u00e4nne","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.cllc.2026.06.003_bib0036","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"issue":"Suppl. 2","key":"10.1016\/j.cllc.2026.06.003_bib0037","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1016\/j.annonc.2023.09.554","article-title":"A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast(DB) -01, -02, and -03","volume":"34","author":"Hurvitz","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.06.003_bib0038","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41523-023-00584-5","article-title":"Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and\/or leptomeningeal disease (ROSET-BM)","volume":"9","author":"Niikura","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"10.1016\/j.cllc.2026.06.003_bib0039","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.cllc.2026.06.003_bib0040","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2026.06.003_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis \u2013 focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"25","key":"10.1016\/j.cllc.2026.06.003_bib0042","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cllc.2026.06.003_bib0043","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2026.06.003_bib0044","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.pupt.2012.06.008","article-title":"Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients","volume":"25","author":"Li","year":"2012","journal-title":"Pulm Pharmacol Ther"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:19:28Z","timestamp":1788866368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1525730426000835"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.06.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non\u2013Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}